{
    "pmcid": "9365158",
    "qa_pairs": {
        "How was the nanobody RBD-1-2G engineered to enhance its neutralization potency?": [
            "By creating bivalent and trivalent formats",
            "By increasing its molecular weight",
            "By adding a fluorescent tag",
            "By incorporating additional mutations in the CDRs"
        ],
        "What challenge does the nanobody RBD-1-2G face with newer SARS-CoV-2 variants?": [
            "Reduced binding against variants with mutations at E484",
            "Increased off-target binding in human cells",
            "Decreased stability after lyophilization",
            "Inability to bind the spike protein in the 'down' conformation"
        ],
        "What is the primary function of the SARS-CoV-2 spike protein as described in the summary?": [
            "Facilitating viral entry by binding to the host cell receptor ACE2",
            "Inhibiting the host immune response",
            "Replicating the viral RNA genome",
            "Assembling new viral particles within the host cell"
        ],
        "What is the significance of the nanobody RBD-1-2G's ability to bind the spike protein in both 'up' and 'partial down' conformations?": [
            "It overlaps with the ACE2 binding site, enhancing neutralization",
            "It prevents the spike protein from undergoing conformational changes",
            "It allows the nanobody to bind to multiple viral proteins",
            "It increases the nanobody's stability in different environmental conditions"
        ],
        "Which mutation in the SARS-CoV-2 spike protein's RBD is mentioned as enhancing binding affinity to ACE2?": [
            "N501Y",
            "D614G",
            "E484K",
            "K417N"
        ]
    }
}